<DOC>
	<DOCNO>NCT01726816</DOCNO>
	<brief_summary>This trial randomize , placebo-controlled , double blind , double dummy , multi-centre trial . - Screening period ( 4 week ) - Double blind treatment period ( 16 week )</brief_summary>
	<brief_title>Efficacy Safety Study Probucol Patients With Diabetic Nephropathy</brief_title>
	<detailed_description>1 . Usage : 16 week , BID , Prescribed Oral breakfast dinner 2 . Dosage : Placebo group : placebo 2 tablet , 16 week Probucol 250mg group : probucol 125mg 2 tablet , 16 week Probucol 500mg group : probucol 250 mg 2 tablet , 16 week</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Probucol</mesh_term>
	<criteria>1 . The subject male female diagnose type 2 diabetes mellitus must age 20 75 year time screen visit 2 . Urinary albumin excretion &gt; 300 mg/g Cr screen visit 3 . Subjects administer ACEI ARB without change dosage prior 3 month screen visit ( subject administer ACEI ARB ) 4 . Subjects administer statin without change dosage prior 3 month screen visit ( subject administer statin ) subject plan administer statin ( subject administer statin ) 5 . 15 mL/min ≤ eGFR ≤ 90 mL min 6 . Subjects must willing able give sign date write informed consent . 1 . Type 1 DM gestational diabetes 2 . Subjects Renal replacement therapy Renal transplantation prior Screening visit 3 . Ventricular arrhythmia ( multiple multifocal premature ventricular contraction ) 4 . Cardiac damage ( abnormally level Troponin I ) 5 . Subject medical history cardiac syncope primary syncope 6 . Has condition may prolong QTc interval ( man QTc interval＞450msec , woman QTc interval＞470msec ) screen 7 . Pregnant lactate woman randomization 8 . Inflammatory bowel disease ( ulcerative colitis , Crohn 's disease ) 9 . Cholestasis 10 . Congestive heart failure 11 . Subjects myocardial infarction , Unstable angina , cerebral infarction within late 6 month 12 . Subjects diagnosis NYHA grade IIIIV status 13 . AST ALT 3.0 time high upper limit normal range 14 . Active hepatitis Or Liver cirrhosis 15 . Subjects Hyperkalemia ( K &gt; 5.5 mEq/L ) 16 . Subjects Renal Artery stenosis 17 . Subjects Malignancy within 5 year time screen visit ( except treat Basal cell carcinoma squamous cell carcinoma ) 18 . Urinary tract disease ( urinary tract infection , Neurogenic bladder ) 19 . Kidney disease ( nephritis , chronic glomerulonephritis polycystic kidney disease ) 20 . Has allergic history probucol 21 . HbA1c &gt; 9 % 22 . Systolic blood pressure ≥ 160 mmHg Diastolic blood pressure ≥ 100 mmHg 23 . Subjects take probucol within 3 month prior Screening 24 . The subject receive investigational product biological agent within 3 month prior screen 25 . Subjects otherwise judge investigator sub investigator inappropriate inclusion trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Diabetic nephropathy</keyword>
	<keyword>Albumin creatinine ratio</keyword>
	<keyword>Probucol</keyword>
</DOC>